Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
View Patent ↗Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
1. A method for inhibiting proliferation of a cancer cell comprising contacting the cancer cell with an antibody that specifically binds to SEQ ID NO: 1 or SEQ ID NO: 6, wherein the antibody is selected from the group consisting of: an antibody having a heavy chain variable region amino acid sequence of SEQ ID NO: 3 and a light chain variable region amino acid sequence of SEQ ID NO: 5, an antibody produced by the hybridoma cell line deposited as ATCC Accession No. PTA-6163, an antibody produced by the hybridoma cell line deposited as ATCC Accession No. PTA-6256, and an antibody produced by the hybridoma cell line deposited as ATCC Accession No. PTA-6330.
2. The method of claim 1 , wherein the cancer cell is selected from the group consisting of: a breast, head/neck, lung, ovarian, stomach and pancreatic cancer cell.
3. The method of claim 1 , wherein the antibody is conjugated to a cytotoxic agent.
4. The method of claim 3 , wherein the cytotoxic agent is auristatin E or auristatin F.
5. The method of claim 1 , wherein the cancer cell is TGF-beta positive.
6. A method for slowing the development of cancer comprising contacting a cancer cell with an antibody that specifically binds to SEQ ID NO: 1 or SEQ ID NO: 6, wherein the antibody is selected from the group consisting of: an antibody a heavy chain variable region amino acid sequence of SEQ ID NO: 3 and a light chain variable region amino acid sequence of SEQ ID NO: 5, an antibody produced by the hybridoma cell line deposited as ATCC Accession No. PTA-6163, an antibody produced by the hybridoma cell line deposited as ATCC Accession No. PTA-6256, and an antibody produced by the hybridoma cell line deposited as ATCC Accession No. PTA-6330.
7. The method of claim 6 wherein the cancer cell is selected from the group consisting of: a breast, head/neck, lung, ovarian, stomach and pancreatic cancer cell.
8. The method of claim 6 , wherein the cancer cell is TGF-beta positive.
9. The method of claim 6 , wherein the antibody is conjugated to a cytotoxic agent.
10. The method of claim 9 , wherein the cytotoxic agent is auristatin E.